• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb

Bristol-Myers Squibb Company BMY

Last Price$61.08Day Change (%)0.10%
Open Price$61.25Day Change ($)0.06
Day Range60.92–62.4252-Week Range51.82–70.87

As of Wed 2/10/2016 6:06:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan

    Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan

  2. Bristol-Myers Squibb to Take Part in Leerink Swann Global Healthcare Conference

    Bristol-Myers Squibb to Take Part in Leerink Swann Global Healthcare Conference

  3. Bristol-Myers Squibb ’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1

    Bristol-Myers Squibb ’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1

  4. Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion for Investigational Antibody, Empliciti (elotuzumab), for the Treatment of Multiple Myeloma in Patients Who Have Received at Least One ...

    Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion for Investigational Antibody, Empliciti (elotuzumab), for the Treatment of Multiple Myeloma in Patients Who Have Received at Least One Prior Therapy

  5. MARKET SNAPSHOT: Apple, Amazon Headline Crucial Week For Wall Street Quarterly Results

    MARKET SNAPSHOT: Apple, Amazon Headline Crucial Week For Wall Street Quarterly Results

  6. UPDATE: Apple, Amazon headline crucial week for Wall Street quarterly results

    UPDATE: Apple, Amazon headline crucial week for Wall Street quarterly results

  7. Allied Minds plc Trading Statement

    Allied Minds plc Trading Statement

  8. Psoriasis Therapeutics Pipeline Review, H2 2015 - Research and Markets

    Psoriasis Therapeutics Pipeline Review, H2 2015 - Research and Markets

  9. Metastatic Colorectal Cancer Pipeline Review, H2 2015 - Research and Markets

    Metastatic Colorectal Cancer Pipeline Review, H2 2015 - Research and Markets

  10. MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor in collaboration with MD Anderson

    MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor in collaboration with MD Anderson

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.